Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|April 27, 2020
Evolving Models in Specialty Pharmacy
Thom Cohn, chief strategy officer, Asembia, discusses recent developments in specialty pharmacy models.
Advertisement
Thom Cohn, chief strategy officer, Asembia, discusses recent developments in specialty pharmacy models.
Thom Cohn: Well, the specialty model is evolving, and there's been a lot of recent developments in specialty pharmacy, whether it's new therapies, digital therapies, digital solutions for patients, or just new ways to interact with patients.
Advertisement
Related to this article
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Once-daily oral deucrictibant extended-release significantly reduced hereditary angioedema attacks compared with placebo in the pivotal phase 3 CHAPTER-3 trial.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
Radioligand Therapy Doesn’t Need to Be Risk-Free—It Needs to Be Worth It
3
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
4
FDA Approves Rebisufligene Etisparvovec as First Gene Therapy for Children With Sanfilippo Syndrome Type A
5